Cross Cancer Institute is the comprehensive cancer centre for northern Alberta. The institute, named for Wallace Warren Cross, is located in Edmonton near the southwest corner of the University of Alberta, and is one of two tertiary cancer centres in the province.

During the past decade, Cross Cancer Institute conducted 284 clinical trials. In the 10-year time frame, 284 clinical trials started and 170 clinical trials were completed, i.e. on average, 59.9% percent of trials that started reached the finish line to date. In the past 5 years, 108 clinical trials started and 82 clinical trials were completed. i.e. 75.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cross Cancer Institute" #1 sponsor was "AHS Cancer Control Alberta" with 133 trials, followed by "Radiation Therapy Oncology Group" with 53 trials sponsored, "NCIC Clinical Trials Group" with 49 trials sponsored, "National Cancer Institute (NCI)" with 34 trials sponsored and "Pfizer" with 34 trials sponsored. Other sponsors include 446 different institutions and companies that sponsored additional 138 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cross Cancer Institute" #1 collaborator was "National Cancer Institute (NCI)" with 142 trials as a collaborator, "Cross Cancer Institute" with 53 trials as a collaborator, "NRG Oncology" with 25 trials as a collaborator, "NCIC Clinical Trials Group" with 23 trials as a collaborator and "SWOG Cancer Research Network" with 18 trials as a collaborator. Other collaborators include 383 different institutions and companies that were collaborators in the rest 198 trials.

According to Clinical.Site data, the most researched conditions in "Cross Cancer Institute" are "Prostate Cancer" (54 trials), "Breast Cancer" (46 trials), "Multiple Myeloma" (34 trials), "Lymphoma" (27 trials) and "Lung Cancer" (25 trials). Many other conditions were trialed in "Cross Cancer Institute" in a lesser frequency.

Most popular intervention types in "Cross Cancer Institute" are "Drug" (539 trials), "Radiation" (138 trials), "Procedure" (107 trials), "Biological" (95 trials) and "Other" (86 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (57 trials), "Placebo" (50 trials), "cyclophosphamide" (23 trials), "cisplatin" (22 trials) and "Dexamethasone" (21 trials). Other intervention names were less common.

The vast majority of trials in "Cross Cancer Institute" are 590 trials for "All" genders, 93 trials for "Female" genders and 70 trials for "Male" genders.

Currently, there are NaN active trials in "Cross Cancer Institute". 9 are not yet recruiting, 101 are recruiting, 101 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 438 completed trials in Cross Cancer Institute, 1 suspended trials, and 52 terminated clinical trials to date.

Out of the total trials that were conducted in Cross Cancer Institute, 108 "Phase 1" clinical trials were conducted, 294 "Phase 2" clinical trials and 309 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 53 trials that are defined as “Not Applicable".